Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Hansen, H. Johansen, T. Pressler, H. Niels (Copenhagen, Denmark). Long-term, low-dose azithromycin treatment reduces the prevalence of staphylococcus aureus, but selects for macrolide resistance in Danish CF-patients. Eur Respir J 2007; 30: Suppl. 51, 3772

Member's Comments

No comment yet.

Related content which might interest you: Chronic use of azithromycin in CF is associated with a substantial increase in macrolide resistance of S. aureus and haemophilus Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs Year: 2006 Treatment challenges in methicillin resistant Staphylococcus aureus infections Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial Source: Eur Respir J 2004; 23: 921-926 Year: 2004 Therapeutic efficacy of macrolides, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006 Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Increasing global resistance to penicillin, macrolides and other antimicrobials among isolates of Streptococcus pneumoniae: susceptibility data from three years of the PROTEKT surveillance study Source: Eur Respir J 2003; 22: Suppl. 45, 486s Year: 2003 Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Source: Eur Respir J 2001; 17: 641-646 Year: 2001 Staphlococcus aureus: susceptibility to antibacterial drugs and rate of MRSA Source: Eur Respir J 2006; 28: Suppl. 50, 788s Year: 2006 Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013 Increasing incidence of fluoroquinolone resistant tuberculosis in Bombay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021 Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002 Mechanisms of acquisition of resistance in Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 S. pneumoniae community-acquired pneumonia (SP-CAP): relationship between mortality and antibiotic susceptibility and risk factors for drug resistance Source: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001 Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance Source: Eur Respir J, 50 (1) 1700598; 10.1183/13993003.00598-2017 Year: 2017 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Long-term linezolid in cystic fibrosis patients chronically colonized with Staphylococcus aureus (SA) Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 The effect of addition of macrolide to a beta-lactam antibiotic on treatment success in patients with moderately severe community acquired pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010